Abstract: Given the large numbers of stimulant NPS having recently been identified from web crawler activities, this chapter comments on the pharmacological, clinical pharmacological, toxicity, and acute/chronic treatment/management issues pertaining to a range of novel stimulants, including psychedelic phenethylamines, novel amphetamine-like molecules, synthetic cathinones, synthetic cocaine...
Abstract Synthetic cannabinoid receptor agonists (SCRAs), originally developed for biomedical research purposes, are now one of the biggest classes of new psychoactive substances (NPS). Due to their higher binding affinity and activity to the cannabinoid receptors, compared to Δ9-THC, they pose a higher pharmacological and toxicological risk for consumers. Different intoxication symptoms (e.g.,...